Cdc2L5 Antibody (ZZ08): sc-81837
- Cdc2L5 Antibody (ZZ08) is a mouse monoclonal IgG1 κ Cdc2L5 antibody provided at 100 µg/ml
- raised against a recombinant protein mapping within amino acids 1-324 representing full length Cdc2L5 of human origin
- recommended for detection of Cdc2L5 of mouse, rat and human origin by WB, IP, IF and ELISA
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for Cdc2L5 Antibody (ZZ08). This work is in progress.
QUICK LINKS
SEE ALSO...
Cdc2L5 Antibody (ZZ08) is a mouse monoclonal IgG1 kappa light chain antibody that detects Cdc2L5 of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Anti-Cdc2L5 antibody (ZZ08) is available as a non-conjugated format. Cdc2L5, also known as cell division cycle 2-like 5 or CHED, is a crucial member of the cyclin-dependent serine/threonine protein kinase family, which plays a significant role in regulating the cell cycle, particularly during mitosis. Cdc2L5 is predominantly expressed in liver, brain, and muscle tissues, where Cdc2L5 is involved in key processes such as cell differentiation and apoptosis. Notably, Cdc2L5 is implicated in blood cell development and is essential for controlling critical events in the mitotic cycle. Cdc2L5 overexpression has been linked to neuroblastoma and glioblastoma progression, highlighting Cdc2L5′s potential role in carcinogenesis. Cdc2L5 contains a protein kinase domain and exists in two isoforms generated through alternative splicing, which may contribute to functional diversity and regulatory mechanisms within the cell.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Cdc2L5 Antibody (ZZ08) References:
- A new subfamily of high molecular mass CDC2-related kinases with PITAI/VRE motifs. | Marqués, F., et al. 2000. Biochem Biophys Res Commun. 279: 832-7. PMID: 11162436
- Bacillus subtilis CheD is a chemoreceptor modification enzyme required for chemotaxis. | Kristich, CJ. and Ordal, GW. 2002. J Biol Chem. 277: 25356-62. PMID: 12011078
- CDC2L5, a Cdk-like kinase with RS domain, interacts with the ASF/SF2-associated protein p32 and affects splicing in vivo. | Even, Y., et al. 2006. J Cell Biochem. 99: 890-904. PMID: 16721827
- CDK13/CDC2L5 interacts with L-type cyclins and regulates alternative splicing. | Chen, HH., et al. 2007. Biochem Biophys Res Commun. 354: 735-40. PMID: 17261272
- Cloning and antisense oligodeoxynucleotide inhibition of a human homolog of cdc2 required in hematopoiesis. | Lapidot-Lifson, Y., et al. 1992. Proc Natl Acad Sci U S A. 89: 579-83. PMID: 1731328
- Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. | Zhang, T., et al. 2016. Nat Chem Biol. 12: 876-84. PMID: 27571479
- Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer. | Quereda, V., et al. 2019. Cancer Cell. 36: 545-558.e7. PMID: 31668947
- Dual Inhibition of CDK12/CDK13 Targets Both Tumor and Immune Cells in Ovarian Cancer. | Cheng, L., et al. 2022. Cancer Res. 82: 3588-3602. PMID: 35857807
- CDK13 phosphorylates the translation machinery and promotes tumorigenic protein synthesis. | Wu, C., et al. 2023. Oncogene. 42: 1321-1330. PMID: 36882522
- Oncogenic CDK13 mutations impede nuclear RNA surveillance. | Insco, ML., et al. 2023. Science. 380: eabn7625. PMID: 37079685
- CDK13 promotes lipid deposition and prostate cancer progression by stimulating NSUN5-mediated m5C modification of ACC1 mRNA. | Zhang, Y., et al. 2023. Cell Death Differ. 30: 2462-2476. PMID: 37845385
- ARID1A loss promotes RNA editing of CDK13 in an ADAR1-dependent manner. | Zhu, T., et al. 2024. BMC Biol. 22: 132. PMID: 38835016
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Cdc2L5 Antibody (ZZ08) | sc-81837 | 100 µg/ml | $333.00 |